Research & Development
FSD Pharma to trade on Nasdaq Capital Market
9 January 2020 -

Pharmaceutical R&D company FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9) said on Wednesday that its Class B subordinate voting shares will begin trading with immediate effect on the Nasdaq Capital Market under the symbol 'HUGE'.

The Class B subordinate voting shares will also continue to trade on the Canadian Securities Exchange under the same symbol.

Describing the NASDAQ listing as a "paradigm shift in the outlook of FSD Pharma", Dr Raza Bokhari, executive co-chairman of the board and CEO, said: "Doing so offers us an opportunity to expand awareness of the company's specialty pharmaceutical lead asset, a micronized formulation of palmitolylethonalamide (micro-PEA), which by targeting the CB2 receptor of the endocannabinoid system of the human body, may help address the opioid crisis by developing opioid-sparing, FDA-approved prescription drugs."

On 13 January Dr Bokhari will present at Biotech Showcase 2020 in San Francisco to provide an overview of the company, as well as recent strides made to transform into a specialty pharmaceutical R&D company.

Along with the company's leadership team, Dr Bokhari also will meet with members of the global investment community while in San Francisco from 13 January to 15 January 2020 on the sidelines of the JPMorgan 38th Annual Healthcare Conference.



Related Headlines